Compare NBIX & GL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | GL |
|---|---|---|
| Founded | 1992 | 1900 |
| Country | United States | United States |
| Employees | N/A | 3695 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 10.7B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | GL |
|---|---|---|
| Price | $130.52 | $152.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $180.91 | $167.27 |
| AVG Volume (30 Days) | ★ 1.1M | 428.2K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $9.64 |
| Revenue Next Year | $13.14 | $5.61 |
| P/E Ratio | $27.99 | ★ $10.21 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $107.96 | $116.73 |
| 52 Week High | $160.18 | $155.08 |
| Indicator | NBIX | GL |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 62.75 |
| Support Level | $124.62 | $135.08 |
| Resistance Level | $135.88 | $152.71 |
| Average True Range (ATR) | 3.58 | 2.99 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 59.98 | 67.63 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.